Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00650936 · ClinicalTrials.gov registry record · NA
Closure of Atrial Septal Defects With the AMPLATZER Septal Occluder - Post Approval Study
A NA study of Atrial Septal Defect, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
- 20
- Study locations
NCT00650936 is a NA study of Atrial Septal Defect that has completed, run by Abbott Medical Devices. The registered enrollment target is 1,000 participants. The trial reports 20 study locations across 9 states.
The verdict
NCT00650936, a NA study of Atrial Septal Defect, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to prospectively evaluate the incidence of hemodynamic compromise and to obtain long-term survival data on patients with the AMPLATZER Septal Occluder
Conditions Studied
Interventions
- DEVICE AMPLATZER Septal Occluder
Study Locations (20)
Florida
- Joe DiMaggio Children's Hospital - Hollywood
- Jacksonville Pediatric Cardiovascular Center - Jacksonville
- Miami Children's Hospital - Miami
- Arnold Palmer Hospital for Children - Orlando
- Tampa General Hospital - Tampa
California
- Kaiser Permanente - Los Angeles
- Children's Hospital of Central California - Madera
- Children's Hospital Oakland - Oakland
- University of California, San Francisco - San Francisco
Colorado
- Aurora Denver Cardiology Associates - Aurora
- Medical Center of the Rockies - Loveland
District of Columbia
- Children's National Medical Center - Washington D.C.
- Washington Hospital Center - Washington D.C.
Illinois
- Rush University Medical Center - Chicago
- Hope Children's Hospital - Oak Lawn
Indiana
- Indiana University - Indianapolis
- Riley Hospital for Children - Indianapolis
Alabama
- University of Alabama at Birmingham - Birmingham
Georgia
- Children's Healthcare of Atlanta - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2007-08 |
| Est. Completion | 2014-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00650936
The ClinicalTrials.gov registry entry for NCT00650936 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atrial Septal Defect appearing as the primary indexed condition, and to 1 intervention - of which AMPLATZER Septal Occluder is the first listed.
NCT00650936 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT00650936 about?
NCT00650936 is a clinical study titled "Closure of Atrial Septal Defects With the AMPLATZER Septal Occluder - Post Approval Study". The purpose of this study is to prospectively evaluate the incidence of hemodynamic compromise and to obtain long-term survival data on patients with the AMPLATZER Septal Occluder
What is the current status of trial NCT00650936?
This trial is currently completed. It is a NA study. The enrollment target is 1,000 participants. The study started on 2007-08. Estimated completion is 2014-06.
What conditions does trial NCT00650936 study?
This clinical trial studies the following conditions: Atrial Septal Defect.
What interventions are being tested in trial NCT00650936?
The interventions under investigation include: AMPLATZER Septal Occluder (DEVICE).
Who is sponsoring clinical trial NCT00650936?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00650936 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.